Doctors Lack Standard Test for Lupus Kidney Disease, Hampering Drug Development
A global team of rheumatologists and nephrologists has identified a critical gap: there's no agreed-upon way to measure whether lupus nephritis treatments actually work. This fragmentation delays drug approvals, complicates clinical trials, and makes it harder for patients to access effective therapies. Standardizing these measures could accelerate treatment innovation in a disease that remains a leading cause of kidney failure.
Originaltitel: A Review and Future Perspective on Renal Outcome Definitions in Lupus Nephritis.
Lupusnefrit saknar standardiserade definitioner för njurutfall — en kritisk flaskhals för jämförbara kliniska studier och valet av behandling. En internationell arbetsgrupp med ledning från Karolinska Institutet har därför utarbetat enhetliga riktlinjer för hur njurpåverkan mäts och klassificeras i framtida försök. Gruppen föresprågar fyra konkreta åtgärder: återkommande njurprover för att bedöma inflammatorisk respons, glomerolos-filtrationshastighet som långsiktigt mått, minskning av glukokortikoidbehov och utökad uppföljning för att fånga varaktiga resultat. Nya biomarkörer bör integreras parallellt med traditionell njurfunktionsmätning. För inköpschefer och regulatörer innebär detta enhetliga kriterier för att bedöma nya immunosuppressiva läkemedel. Standardiseringen möjliggör mer meningsfulla jämförelser mellan behandlingar och snabbar upp godkännandeprocesser för avancerad terapi mot denna allvarliga sjukdom.
Lupus nephritis (LN) remains a leading cause of morbidity and mortality in systemic lupus erythematosus, yet the lack of standardized definitions for renal outcomes hinders effective diagnosis, prognosis, treatment personalization, comparisons across trials, and interpretable trial endpoints. Despite significant advances in biomarker discovery, treatment strategies, and histopathological classification, substantial challenges and controversies persist in defining and assessing renal response to therapy. Following a January 2025 roundtable discussion on the subject of LN outcome definitions, a workgroup was established to address these issues and provide an expert perspective on the future of outcome definitions based on current literature. Here, we examine the current limitations of renal outcome definitions and advocate for change toward improved interpretation and comparison of clinical study data. Key areas, such as limitations of traditional kidney function markers and the need for reliable endpoints reflecting improvements in renal inflammation in trials, are addressed. As an international workgroup of rheumatologists and nephrologists with experience in managing LN, we advocate for a unified approach considering standard per-protocol repeat biopsies for histologic response evaluation, estimated glomerular filtration rate slope, glucocorticoid minimization/withdrawal, and extended follow-up for the evaluation of sustained long-term outcomes. The importance of harmonizing clinical and histologic definitions and the potential of novel biomarkers are highlighted. Herein, we provide a perspective toward uniform definitions of response in LN trials, renal flare/relapse, and refractory disease with improved applicability, especially in the context of advanced immunosuppressives. Thereby, we aim to facilitate meaningful study and advanced treatment of LN, ultimately enhancing patient outcomes and future research.